Clinical Report: Genetic Influence of Peripheral B Cell Immune Dysregulation on Neuroinflammation in Parkinson’s Disease

Overview

This study identifies genetically influenced B-cell gene expression as a contributor to peripheral immune dysregulation in Parkinson's disease (PD). Eight high-confidence MR causal genes were prioritized, suggesting potential therapeutic targets for future validation.

Background

Parkinson's disease is a prevalent neurodegenerative disorder characterized by dopaminergic neuron loss and neuroinflammation. The role of the peripheral immune system, particularly B cells, in PD pathogenesis is increasingly recognized, yet the genetic underpinnings remain poorly understood. Identifying reliable biomarkers and therapeutic targets is crucial for advancing treatment options in PD.

Data Highlights

Key Findings

• Eight high-confidence MR causal genes were identified, including five risk-increasing and three protective genes.
• Early-change genes showed expression differences detectable as early as PD-Early in a small exploratory cohort.
• Naive B and Atypical B cells were enriched in specific gene expressions related to PD.
• The MIF signaling pathway communication probability increased significantly from healthy controls to late-stage PD.
• Molecular docking suggested structural plausibility for small-molecule interactions with candidate targets.

Clinical Implications

Highlight the necessity for clinical trials to test the proposed therapeutic strategies.

Conclusion

Stress the need for further experimental validation of the identified therapeutic candidates.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Acta Neuropathologica, 2021 -- Immune System Dynamics in Parkinson’s Disease: Insights from Peripheral and Central Mechanisms
3. Author(s)/Org, Acta Neuropathologica, 2020 -- Comprehensive Analysis of Pathway-Specific Polygenic Risk and Transcriptomic Networks Reveals New Functional Pathways in Parkinson's Disease
4. Author(s)/Org, NICE, 2024 -- Overview | Parkinson’s disease in adults | Guidance
5. Acta Neuropathologica — The Role of Inflammation in the Development of ALS and FTD
6. Overview | Parkinson’s disease in adults | Guidance | NICE
7. Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study - PubMed
8. A moderator-mediator analysis of inflammatory cytokine levels in Parkinson’s disease: A systematic review and meta-analysis